5-Fluoro-4-methyl-6-(piperidin-4-ylmethyl)-1,4-benzoxazin-3-one | 795273-57-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 5-Fluoro-4-methyl-6-(piperidin-4-ylmethyl)-1,4-benzoxazin-3-one
• CAS: 795273-57-3
• 化学式: C₁₅H₁₉FN₂O₂
• 分子量: 278.326
• InChiKey: UXDOPVJHXWVOGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-Fluoro-4-methyl-6-(piperidin-4-ylmethyl)-1,4-benzoxazin-3-one 、 5-(2-bromoethoxy)-2-methylquinoline 在 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 异丙醇 为溶剂， 反应 48.0h， 生成 5-fluoro-4-methyl-6-(4-(1-(2-(5-(2-methyl)-quinolinyloxy)-ethyl)-piperidinyl)-methyl)-4H-benzo[1,4]oxazin-3-one
  参考文献：
  名称：

  [EN] BENZOXAZINONE DERIVATIVES HAVING AFFINITY FOR 5- HT RECEPTORS, THEIR PREPARATION AND USE
  [FR] DERIVES DE BENZOXAZINONE POSSEDANT UNE AFFINITE AVEC DES RECEPTEURS 5-HT, PREPARATION ET UTILISATION DE CEUX-CI

  摘要：

  苯并噁唑酮衍生物，它们的制备和用途是公开的：其中R1是氢或C1-6烷基；R2是氟或氯；R3是氢、氟或氯；X是氮或CH。还公开了其制备方法和在治疗中枢神经系统疾病，如抑郁症或焦虑症中的用途。

  公开号：

  WO2004099198A1
• 作为产物：
  描述：

  6-(4-(N-(t-butyloxycarbonyl)piperidinyl)methyl)-5-fluoro-4H-benzo[1,4]oxazin-3-one 在 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 5-Fluoro-4-methyl-6-(piperidin-4-ylmethyl)-1,4-benzoxazin-3-one
  参考文献：
  名称：

  Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands

  摘要：

  A series of 5-(piperidinylethyloxy)quinoline 5-HT1 receptor ligands have been studied by elaboration of the series of dual 5-HT1-SSRIs reported previously. These new compounds display a different pharmacological profile with potent affinity across the 5-HT1A, 5-HT1B and 5-HT1D receptors and selectivity against the serotonin transporter. Furthermore, they have improved pharmacokinetic profiles and CNS penetration. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.078

文献信息

• [EN] BENZOXAZINONE DERIVATIVES HAVING AFFINITY FOR 5- HT RECEPTORS, THEIR PREPARATION AND USE<br/>[FR] DERIVES DE BENZOXAZINONE POSSEDANT UNE AFFINITE AVEC DES RECEPTEURS 5-HT, PREPARATION ET UTILISATION DE CEUX-CI
  申请人：GLAXO GROUP LTD

  公开号：WO2004099198A1

  公开（公告）日：2004-11-18

  Benzoxazinone derivatives, their preparation and use Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: (I) wherein R1 is hydrogen or C1-6alkyl; R2 is fluoro or chloro; R3 is hydrogen, fluoro or chloro; and X is nitrogen or CH. Methods of preparation and uses thereof in treatment of CNS disorders, such as depression or anxiety, are also disclosed.

  苯并噁唑酮衍生物，它们的制备和用途是公开的：其中R1是氢或C1-6烷基；R2是氟或氯；R3是氢、氟或氯；X是氮或CH。还公开了其制备方法和在治疗中枢神经系统疾病，如抑郁症或焦虑症中的用途。
• Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands
  作者：Simon E. Ward、Christopher N. Johnson、Peter J. Lovell、Claire M. Scott、Paul W. Smith、Geoffrey Stemp、Kevin M. Thewlis、Antonio K. Vong、Jeannette M. Watson

  DOI：10.1016/j.bmcl.2007.06.078

  日期：2007.9

  A series of 5-(piperidinylethyloxy)quinoline 5-HT1 receptor ligands have been studied by elaboration of the series of dual 5-HT1-SSRIs reported previously. These new compounds display a different pharmacological profile with potent affinity across the 5-HT1A, 5-HT1B and 5-HT1D receptors and selectivity against the serotonin transporter. Furthermore, they have improved pharmacokinetic profiles and CNS penetration. (c) 2007 Elsevier Ltd. All rights reserved.